{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '97', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'It is best practice and strongly recommended that the ePROs are administered to randomized', 'participants before drug administration, AE evaluation, and disease status notification. If the', 'participant does not complete the ePROs at a scheduled time point, the MISS MODE form', 'must be completed to capture the reason the assessment was not performed.', '8.3', 'Safety Assessments', 'Details regarding specific safety procedures/assessments to be performed in this study are', 'provided. Planned time points for all safety assessments are provided in the SoA.', '8.3.1', 'Physical Examinations', 'The investigator or qualified designee will perform a complete physical examination during', 'the screening period. Clinically significant abnormal findings should be recorded as medical', 'history. The time points for full physical examination are described in the SoA (Section 1.3).', 'After the first dose of study treatment, new clinically significant abnormal findings should be', 'recorded as AEs.', 'For cycles that do not require a full physical examination per the SoA (Section 1.3), the', 'investigator or qualified designee will perform a directed physical examination as clinically', 'indicated before study treatment administration. New clinically significant abnormal findings', 'should be recorded as AEs.', 'Investigators should pay special attention to clinical signs related to previous serious', 'illnesses.', '8.3.2', 'Vital Signs', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed', 'from the study. Repeat BP measurements for monitoring participants receiving', 'lenvatinib are no longer required. This section has been updated accordingly.', 'The investigator or qualified designee will take vital signs at screening, before the', 'administration of each dose of study treatment and during the follow-up period, as specified', 'in the SoA (Section 1.3). Vital signs include temperature, heart rate, respiratory rate, weight,', 'and blood pressure. Height will be measured at Visit 1 only.', '8.3.3', 'Electrocardiograms', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed', 'from the study. Additional ECG measurements for monitoring participants receiving', 'lenvatinib are no longer required. This section has been updated accordingly.', 'Electrocardiograms (ECGs) will be obtained as designated in the SoA (Section 1.3).', 'Complete, standardized, 12-lead ECG recordings that permit all 12 leads to be displayed on a', 'single page with an accompanying lead II rhythm strip below the customary 3 X 4 lead', 'format are to be used. In addition to a rhythm strip, a minimum of 3 full complexes should be', 'recorded from each lead simultaneously. Participants must be in the recumbent position for a', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '98', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'period of 5 minutes prior to the ECG. The Fridericia correction method for calculating QTc', 'will be used.', 'An ECG abnormality may meet the criteria of an AE as described in this protocol (see', 'Appendix 3) and the eCRF Entry Guidelines. In these instances, the AE corresponding to the', 'ECG abnormality will be recorded on the appropriate case report form (CRF).', '8.3.4 Echocardiograms or Multigated Acquisition Scans', 'A MUGA scan (using a technetium-based tracer) or an ECHO will be performed to assess', 'LVEF as designated in the SoA (Section 1.3). Additional assessments may be performed as', 'clinically indicated.', \"MUGA scans or ECHOs should be performed locally in accordance with the institution's\", 'standard practice. MUGA scans are the preferred modality. However, whichever modality is', 'used for an individual participant at baseline should be repeated for all subsequent LVEF', 'assessments for that participant.', 'LVEF, as assessed by the institution, will be entered in the electronic case report form', '(eCRF). Investigator assessment will be based on institutional reports.', '8.3.5', 'Clinical Safety Laboratory Assessments', '8.3.5.1', 'Laboratory Safety Evaluations (Hematology, Chemistry and Urinalysis)', 'Refer to Appendix 2 for the list of clinical laboratory tests to be performed and to the', 'SoA for the timing and frequency.', 'The investigator or medically qualified designee (consistent with local requirements)', 'must review the laboratory report, document this review, and record any clinically', 'relevant changes occurring during the study in the AE section of the case report form', '(CRF). The laboratory reports must be filed with the source documents. Clinically', 'significant abnormal laboratory findings are those which are not associated with the', 'underlying disease, unless judged by the investigator to be more severe than expected', \"for the participant's condition.\", 'CBC with differential and clinical chemistry results must be reviewed before', 'administration of study intervention. Electrolytes such as potassium, calcium, and', 'magnesium should be monitored and abnormalities, when considered clinically', 'significant, should be corrected in all participants before starting study intervention.', 'All protocol-required laboratory assessments, as defined in Appendix 2, must be', 'conducted in accordance with the laboratory manual and the SoA.', 'If laboratory values from nonprotocol specified laboratory assessments performed at', \"the institution's local laboratory require a change in study participant management or\", 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}